Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AVX901 |
Synonyms | |
Therapy Description |
AVX901 is a virally based vaccine that infects cells and causes expression of a ERBB2 (HER2) ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against ERBB2 (HER2)-expressing tumor cells (PMID: 29081765). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AVX901 | DUKE-002-VRP|HER2 ECDTM VRP|HER2 VRP|VRP-HER2|VRP-neu | HER2 (ERBB2) Vaccine 14 | AVX901 is a virally based vaccine that infects cells and causes expression of a ERBB2 (HER2) ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against ERBB2 (HER2)-expressing tumor cells (PMID: 29081765). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03632941 | Phase II | Pembrolizumab AVX901 + Pembrolizumab AVX901 | A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer | Active, not recruiting | USA | 0 |
NCT01526473 | Phase I | AVX901 | A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 | Completed | USA | 0 |